An issue of Endo International plc – (NASDAQ:ENDP) (TSE:ENL) bonds rose 1.3% as a percentage of their face value during trading on Monday. The high-yield issue of debt has a 6% coupon and will mature on July 15, 2023. The bonds in the issue are now trading at $75.78 and were trading at $75.00 one week ago. Price moves in a company’s bonds in credit markets sometimes anticipate parallel moves in its share price.
ENDP has been the subject of several research reports. Mizuho restated a “buy” rating and set a $12.00 price objective (down from $14.00) on shares of Endo International in a research note on Wednesday, January 3rd. Leerink Swann initiated coverage on shares of Endo International in a research note on Tuesday, January 2nd. They set an “outperform” rating and a $12.00 price objective for the company. Vetr upgraded shares of Endo International from a “buy” rating to a “strong-buy” rating and set a $8.92 price objective for the company in a research note on Tuesday, December 26th. Zacks Investment Research cut shares of Endo International from a “hold” rating to a “sell” rating in a research note on Monday, January 15th. Finally, BidaskClub cut shares of Endo International from a “sell” rating to a “strong sell” rating in a research note on Wednesday, January 31st. Three investment analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $10.22.
Shares of Endo International plc – (NASDAQ ENDP) traded up $0.04 during midday trading on Monday, reaching $7.02. 3,000,000 shares of the company traded hands, compared to its average volume of 5,420,000. The stock has a market cap of $1,560.00, a price-to-earnings ratio of -1.27 and a beta of 0.35. The company has a debt-to-equity ratio of 17.00, a quick ratio of 0.85 and a current ratio of 1.02. Endo International plc – has a 12 month low of $5.77 and a 12 month high of $14.15.
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Elkfork Partners LLC purchased a new stake in Endo International in the 4th quarter worth $194,000. Xact Kapitalforvaltning AB purchased a new stake in Endo International in the 4th quarter worth $157,000. Hunter Associates Investment Management LLC increased its holdings in Endo International by 53.7% in the 4th quarter. Hunter Associates Investment Management LLC now owns 67,150 shares of the company’s stock worth $520,000 after acquiring an additional 23,450 shares in the last quarter. Paloma Partners Management Co purchased a new stake in Endo International in the 4th quarter worth $122,000. Finally, Quantitative Investment Management LLC purchased a new stake in Endo International in the 4th quarter worth $1,569,000. 96.54% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: “Endo International (ENDP) Debt Trading 1.3% Higher” was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this piece on another site, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The correct version of this piece can be viewed at https://sportsperspectives.com/2018/03/12/endo-international-endp-debt-trading-1-3-higher.html.
About Endo International
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.